Understanding COVID-19 vaccine hesitancy
Nat Med
.
2021 Aug;27(8):1338-1339.
doi: 10.1038/s41591-021-01459-7.
Authors
Shingai Machingaidze
#
1
2
,
Charles Shey Wiysonge
#
3
4
Affiliations
1
European and Developing Countries Clinical Trials Partnership, Africa Office, Cape Town, South Africa. machingaidze@edctp.org.
2
School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. machingaidze@edctp.org.
3
School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
4
Cochrane South Africa, South African Medical Research Council, Cape Town, South Africa.
#
Contributed equally.
PMID:
34272500
DOI:
10.1038/s41591-021-01459-7
No abstract available
Publication types
Comment
MeSH terms
COVID-19 Vaccines
COVID-19*
Humans
SARS-CoV-2
Vaccination
Substances
COVID-19 Vaccines